INT192073

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 10.35
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (ADA) aging (ADA) cytoplasm (ADA)
cytosol (ADA) extracellular space (ADA) cell adhesion (ADA)
Anatomy Link Frequency
visceral 6
ADA (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 211 100.00 Very High Very High Very High
Infliximab 65 99.56 Very High Very High Very High
Central nervous system 18 99.16 Very High Very High Very High
cva 20 86.64 High High
headache 12 86.12 High High
adenocard 55 77.28 Quite High
cytokine 8 59.48 Quite High
Inflammation 19 57.24 Quite High
corticosteroid 20 49.80 Quite Low
withdrawal 2 44.36 Quite Low
Disease Link Frequency Relevance Heat
Central Nervous System Disease 2 99.52 Very High Very High Very High
Fever 245 99.28 Very High Very High Very High
Diabetes Mellitus 25 99.24 Very High Very High Very High
Mycobacterial Infection 184 98.68 Very High Very High Very High
Communicable Diseases 16 97.80 Very High Very High Very High
Disease 146 97.36 Very High Very High Very High
Cardiovascular Disease 35 97.32 Very High Very High Very High
Viral Meningitis 12 96.28 Very High Very High Very High
Bacterial Pneumonia 8 93.60 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 24 92.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In conclusion, we showed that ADA and XO levels were increased in patients with CCHF.
Positive_regulation (increased) of Gene_expression (levels) of ADA associated with fever
1) Confidence 0.47 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.06 Pain Relevance 0.10
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Positive_regulation (Increased) of Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
2) Confidence 0.47 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.51 Pain Relevance 0.11
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Positive_regulation (Increased) of Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
3) Confidence 0.47 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.51 Pain Relevance 0.11
Increased serum/plasma ADA activity, comprising both ADA-1 and ADA-2 activity, has been used as a biochemical marker for infectious diseases.22–24 Increased serum ADA has been reported in infectious diseases such as viral and bacterial pneumonia, HIV infection, extra-pulmonary and pulmonary tuberculosis, visceral leishmaniasis, and mononucleosis.21,22,25
Positive_regulation (Increased) of Gene_expression (comprising) of ADA in visceral associated with leishmaniasis, mycobacterial infection, bacterial pneumonia, acquired immune deficiency syndrome or hiv infection, communicable diseases and infection
4) Confidence 0.47 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.45 Pain Relevance 0.11
Patients received ADA 160/80 mg, followed by 80 mg every other week.
Positive_regulation (received) of Gene_expression (received) of ADA associated with adalimumab
5) Confidence 0.42 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 1.00 Pain Relevance 0.39
Similarly increased CSF ADA levels have been reported in childhood TBM with adverse neurological outcome [27].
Positive_regulation (increased) of Gene_expression (levels) of ADA associated with mycobacterial infection
6) Confidence 0.34 Published 2006 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1448186 Disease Relevance 1.51 Pain Relevance 0.05
Approximately 3 ml of CSF was obtained; 2 ml of CSF was used for total and differential cell count, biochemistry, and smear for Gram's, India ink, and acid fast bacilli (AFB) staining and the remaining CSF was used for ADA estimation.
Positive_regulation (used) of Gene_expression (estimation) of ADA
7) Confidence 0.34 Published 2006 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1448186 Disease Relevance 0.85 Pain Relevance 0.26
In type 2 diabetic patients, the proposed target for LDL-C is <100 mg/dL (2.59 mmol/L), while in 2008 the ADA proposed LDL-C to be <70 mg/dL (1.81 mmol/L) in patients with diabetes and CVD.2
Positive_regulation (-) of Gene_expression (proposed) of ADA associated with cardiovascular disease and diabetes mellitus
8) Confidence 0.12 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 1.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox